Key terms
About IMNN
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IMNN news
Apr 11
8:13am ET
Imunon reports compliance with Nasdaq listing requirements
Apr 01
6:20am ET
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)
Apr 01
6:15am ET
Imunon price target raised to $13 from $12 at H.C. Wainwright
Mar 28
8:06am ET
Imunon sees cash runway into 4Q24
Mar 28
8:05am ET
Imunon reports 2023 EPS ($2.16) vs. ($5.03) last year
Mar 25
8:53am ET
Imunon receives $1.3M from sale of New Jersey NOLs
Mar 13
12:30pm ET
Analysts Offer Insights on Healthcare Companies: Imunon (IMNN) and CalciMedica (CALC)
Mar 13
12:15pm ET
Imunon timelines unchanged despite CEO departure, says H.C. Wainwright
Mar 13
8:19am ET
Imunon files IND application to begin human testing of IMNN-101
Mar 12
5:23pm ET
Imunon Announces CEO Resignation and Interim Leadership Transition
Mar 12
5:01pm ET
Imunon CEO Le Goff resigns
Feb 29
8:40am ET
Imunon announces lab confirms immunogenicity, protection with IMNN-101
Feb 27
8:40am ET
Imunon announces Memorial Sloan Kettering Cancer center enrolling patients
Feb 22
8:21am ET
Imunon announces article on IMNN-101 preclinical data
No recent press releases are available for IMNN
IMNN Financials
Key terms
Ad Feedback
IMNN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IMNN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range